Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial.
Fiche publication
Date publication
septembre 2019
Journal
Clinical cardiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Rossello X, Pitt B, Rossignol P, Zannad F
Lien Pubmed
Résumé
Trials using mineralocorticoid receptor antagonists (MRAs) in myocardial infraction (MI) without heart failure (HF) or systolic impairment have been underpowered to assess morbidity-mortality benefit. In EPHESUS 6632 patients were included, of whom 11% had an ejection fraction (EF) of 40% and HF or diabetes. We aim to assess the potential benefit of MRAs in MI with EF of 40%.
Mots clés
ejection fraction, eplerenone, mineralocorticoid receptor antagonists, myocardial infarction, treatment effect
Référence
Clin Cardiol. 2019 Sep 3;: